ASLAN Pharma Selects PharmaNet/i3 as Strategic Partner

ASLAN Pharmaceuticals has selected PharmaNet/i3 as a strategic partner to support the development of its oncology portfolio in Asia, and to conduct Phase I and Phase II trials for two of ASLAN’s compounds.
 
Dr. Alan Barge, ASLAN’s chief medical officer, said, “We chose to work with PharmaNet/i3 because of the commitment and passion shown by their team and the creative thinking they brought to our oncology development strategy. ASLAN is keen to build a strong strategic relationship with PharmaNet/i3, a company that shares our focus on quality and efficiency.”
  
“Clinical development of oncology therapeutics requires a special understanding of the mechanism of action and the different approaches to cancer therapies,” said Dalvir Gill, Ph.D., president of Phase II – IV Development at PharmaNet/i3. “ASLAN has a novel and creative approach to personalized medicine and combination therapy. We will work closely with ASLAN to address the unique methodologies needed to evaluate the efficacy and safety of their innovative products and look forward to a long and productive relationship.”